Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study델타 변이체(B.1.617.2) 및 스코틀랜드 환자의 2차 접종 이후 경과 시간(REACT-SCOT)과 관련된 중증 COVID-19에 대한 백신 효능: 사례-대조군 연구Article Published on 2022-06-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] 95% CI age Alpha Analysis ascertainment bias B.1.1.7 B.1.617.2 booster doses Case-control case-control study ChAdOx1 ChAdOx1 vaccine classification coded community health Control controls COVID-19 Critical care database death declined decrease defined delta variant diagnosed dose Efficacy expected first positive Follow-up hospitalisation include index measure Moderna mRNA mRNA vaccine mRNA vaccines not limited outcome Patient Pfizer predominant presenting primary care primary outcome measure Protective replaced replacement report reported reversed risk SARS-CoV-2 variant Scottish second dose selected Severe case severe cases severe COVID-19 severe disease severity Sex study period suggested Support transmission rate transmission rates vaccination Vaccine vaccine efficacy Vaccines variant [DOI] 10.1016/S2213-2600(22)00045-5 PMC 바로가기 [Article Type] Article
Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach단백질 스캐폴드에 이식된 수용체 결합 모티프가 있는 SARS-CoV-2 면역원의 설계 및 특성화: 에피토프 중심 백신 접근 방식Article Published on 2022-06-012022-09-12 Journal: International journal of biological macromolecules [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] ACE2 angiotensin Antibody Response antigenic approach caused COVID-19 pandemic effective epitope healthcare immunized immunized mice Immuno-focusing induce Infectious disease interferon γ mice natural infection neutralization neutralizing antibody Non-neutralizing antibodies non-neutralizing epitope predominant Protein RBD RBM Receptor binding domain receptor binding motif robust SARS-CoV-2 SARS-COV-2 infection Scaffold sera Spread T cell T cell response the antibody response the disease the spike protein Vaccine [DOI] 10.1016/j.ijbiomac.2022.04.148 PMC 바로가기 [Article Type] Article
SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levelsmRNA 백신을 접종한 개인의 SARS-CoV-2 감염은 스파이크 E484K를 인코딩하는 바이러스에 대해 편향되어 있으며 호흡기 항바이러스성 IgG 수준과 상관관계가 있는 감소된 감염성 바이러스 부하와 관련이 있습니다.Article Published on 2022-06-012022-09-11 Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] A significant reduction accompanied Alpha Alpha variant Amino acid Analysis Anti-viral Antiviral association B.1.1.7 B.1.526 BNT162b2 Breakthrough infection breakthrough infections caused Cell culture change Cohort collected COVID-19 cycle threshold dose E484K early phase ELISA examined Genome ICU admission IgG IgG level IgG levels immunization increase in Infectious virus investigated Lineage Moderna molecular Mortality mRNA mRNA-1273 PCR Pfizer-BioNTech positive positive sample Positive test predominant Protein reduce reduced required respiratory respiratory sample Respiratory samples Sample SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 positive patient sequenced Sequencing specimen specimens spike Spike protein symptomatic infection symptomatic infections upper respiratory tract vaccinated individual vaccinated individuals vaccination Vaccines variant Viral Viral load viral loads viral variant virus were used whole genome [DOI] 10.1016/j.jcv.2022.105151 PMC 바로가기 [Article Type] Article
Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cellsSARS-CoV-2의 숙주 세포 내로의 PI4KB 의존성 세포내이입 진입에는 ACE2의 세포질 도메인 및 효소 활성이 필요하지 않습니다Article Published on 2022-06-012022-09-11 Journal: Virologica Sinica [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 addition angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 Angiotensin converting enzyme 2 (ACE2) catalytic activity causative agent Cell cellular cellular entry cellular receptor clathrin Clathrin-mediated endocytosis COVID-19 pandemic delta variant demonstrated dependent on domain effective endocytosis entry of SARS-CoV-2 enzymatic activity enzyme health emergency host cell host cells human angiotensin converting enzyme 2 infections intracellular domain lentivirus Phosphoinositides PI4KB predominant principle pseudotype required SARS-CoV-2 Spike protein syncytium syncytium formation treat variant viral entry virus entry [DOI] 10.1016/j.virs.2022.03.003 PMC 바로가기 [Article Type] Article
Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trialCOVID-19 관련 호흡 부전(INOCOV) 환자의 일시적인 호흡 안정화로서 흡입된 산화질소: 무작위 대조 시험을 위한 연구 프로토콜Article Published on 2022-05-272022-09-11 Journal: PLoS ONE [Category] 임상, [키워드] Acute respiratory failure adjunct airway anaesthesia blinded Blood cause of death COVID-19 death deoxygenated described End-Expiratory Pressure EudraCT fraction global public health High-flow oxygen Hypoxemia hypoxia Inhaled initial intubation life-threatening lung Lungs management margin measure mechanical ventilation nitric oxide no difference null hypothesis oxygen oxygen saturation pandemic Patient patients with COVID-19 PEEP pharmacological Positive end-expiratory pressure predominant preoxygenation primary outcome measure protocol Randomized Randomized controlled trial reduce Respiratory failure safety margin sequence severe hypoxia Shunt SpO2 Standard of care Trial Two-arm Ventilation WHO [DOI] 10.1371/journal.pone.0268822 PMC 바로가기 [Article Type] Article
Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico멕시코에서 SARS-CoV-2 델타 변이의 세 하위 계통의 지배Article Published on 2022-05-272022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] analyzed available data circulating variant circulation country COVID-19 pandemic Delta delta variant described distributions dominance genomic Genomic surveillance Haplotype highlight include less Mutation North Other over phylogenetic analyses Phylogenetic analysis predominant Prevalence public health reached replaced SARS-CoV-2 SARS-CoV-2 genomic surveillance SARS-CoV-2 isolate SARS-CoV-2 isolates sequence sequences Spread the SARS-CoV-2 Transmission variant variants variants of concern [DOI] 10.3390/v14061165 PMC 바로가기 [Article Type] Article
Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding-Who Is Binding Who and Why?IgG1 및 IgG3 SARS-CoV-2 스파이크 단백질 및 뉴클레오캡시드 결합의 결정 - 누가 누구와 왜 결합합니까?Article Published on 2022-05-272022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] acute respiratory distress acute respiratory distress syndrome Analysis antibody ARDS bind binding characteristic complement convalescent convalescent patient convalescent plasma COVID-19 cytokine cytokine release demonstrated Determination Differential analysis examined flight Glycation glycosylation humoral immune response IgG IgG1 IgG3 Immunoglobulin implicated indicated infected with SARS-CoV-2 mass spectrometry molecular mechanism nucleocapsid nucleocapsids Pathogenesis plasma samples Predictive predictive profile predominant Protein protein G respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-COV-2 infection spectral analysis spike Spike protein Spike proteins stimulate syndrome the spike protein thought [DOI] 10.3390/ijms23116050 PMC 바로가기 [Article Type] Article
Multicenter Evaluation of the BioFire Respiratory Panel 2.1 (RP2.1) for Detection of SARS-CoV-2 in Nasopharyngeal Swab Samples비인두 면봉 샘플에서 SARS-CoV-2 검출을 위한 BioFire Respiratory Panel 2.1(RP2.1)의 다기관 평가Multicenter Study Published on 2022-05-182022-09-11 Journal: Journal of Clinical Microbiology [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adenovirus age Analysis assays BioFire cause Characteristics Concentration coronavirus detection enterovirus exhibited exhibiting expansion groups Hemisphere Human Human rhinovirus imperative incidence include limit of detection multicenter multiplex nasopharyngeal nasopharyngeal swabs overlap Panel pathogen Pathogens positive predominant respiratory respiratory infection respiratory infections respiratory panel 2.1 Respiratory pathogens rhinovirus RP2 Sample SARS-CoV-2 severe acute respiratory syndrome Coronavirus specimen specimens subject target tested [DOI] 10.1128/jcm.00066-22 PMC 바로가기 [Article Type] Multicenter Study
Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial성인을 위한 SARS-CoV-2 비활성화 백신의 3회 용량 요법의 면역원성 및 안전성: 무작위, 이중 맹검, 위약 대조 2상 시험Clinical Trial Published on 2022-05-162022-09-12 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 3-dose regimen acute respiratory syndrome Adults Adverse AEs antibody Antibody Response Control coronavirus dose doses double-blind Effective vaccines elicited event geometric mean titer GMT GMTs immune response immunogenicity Immunoglobulin inactivated Inactivated vaccine Injection-site pain intensity Neutralizing Neutralizing antibodies Older pandemic percentage Phase 2 Placebo placebo-controlled trial predominant pseudovirus Randomized receive Receptor binding domain robust Safety safety profile SARS-CoV-2 SARS-CoV-2 inactivated vaccine second dose separated serious AE tested the vaccine vaccination Vaccine virus were recorded [DOI] 10.1093/infdis/jiab627 PMC 바로가기 [Article Type] Clinical Trial
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel이스라엘의 오미크론에 대한 BNT162b2의 4차 투여에 의한 보호Article Published on 2022-05-052022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age Analysis B.1.1.529 BNT162b2 BNT162b2 vaccine coronavirus coronavirus disease Coronavirus disease 2019 database dose doses eligible estimation Factor groups Infection Internal control Ministry of Health of BNT162b2 Older omicron predominant protection Rate receipt SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 Sex short-lived study period Vaccine variant of SARS-CoV-2 waned [DOI] 10.1056/NEJMoa2201570 PMC 바로가기 [Article Type] Article